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The data presented here are related to the research article entitled
“Estradiol-independent modulation of breast cancer transcript
proﬁle by 17beta-hydroxysteroid dehydrogenase type 1” (J.A. Aka,
E.L. Calvo, S.X. Lin, 2016) [1]. We evaluated the effect of the ster-
oidal enzyme 17β-HSD1 and its product, the estrogenic hormone
17-beta-estradiol (E2), on gene transcription proﬁle of breast
cancer cells. RNA interference technique was used to knock down
the 17β-HSD1 gene (HSD17B1) in the hormone-dependent breast
cancer cell line T47D in steroid-deprived medium. Transfected cells
were subsequently treated with E2, and microarray analyses (with
three contrasts) were used to investigate (i) the effect of 17β-HSD1
expression on breast cancer cell transcript proﬁle in steroid-
deprived condition, (ii) the effect of E2 on breast cancer gene
expression and (iii) if E2 affects gene regulation by 17β-HSD1.
Functional enrichments of the differentially expressed genes were
assessed using Ingenuity Pathway Analysis (IPA). Here, we showed
data on 140 genes that are induced or repressed 1.5 time or higher
(p o 0.05) in the HSD17B1-silenced and E2-treated T47D cells
revealed by microarray analysis, and presented the 14 functional
terms found in the cancer and in the cell death and survivalvier Inc. This is an open access article under the CC BY license
/j.jprot.2016.10.001
docrinology and Oncology, Axe Molecular Endocrinology and Nephrology,
nte-Foy, Québec, G1V 4G2 Canada.
ka), sheng-xiang.lin@crchul.ulaval.ca (S.-X. Lin).
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J.A. Aka et al. / Data in Brief 9 (2016) 1000–1012 1001categories revealed by the IPA biological function analysis. Data on
IPA Canonical Pathway and network analyses is also presented.
Further discussion on gene regulation by 17β-HSD1 and E2 is
provided in the accompanying publication [1].
& 2016 The Authors. Published by Elsevier Inc. This is an open
access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Speciﬁcations Tableubject area Biology
ore speciﬁc
subject areaBreast cancerype of data Table, Figure
ow data was
acquiredMicroarray analysis: microarray was processed using Affymetrix GeneChip
Whole Transcript (WT) Sense Target Labeling Assay and quantiﬁed Affymetrix
image ﬁles were analyzed using the Bioconductor package OneChannelGUI
into the statistical software environment R.
Bioinformatics analysis: functional enrichment analysis was done using the
gene list from the microarray analysis and Ingenuity pathway core analysis
(IPA
s
, QIAGEN Redwood City).
ata format Analyzed and ﬁltered data
xperimental
factorsT47D cells were transfected with 17β-HSD1 siRNAs followed by estradiol
treatment two days later for an additional two days, and total RNA was
extracted for analysis.xperimental
features3105 T47D cells were transfected in 6-well plates in charcoal-treated
medium with 200 nM mixed 17β-HSD1 speciﬁc siRNAs or with negative
control siRNA. Two days later, transfected cells were treated with 1 nM
estradiol or ethanol as a vehicle control in fresh charcoal-treated medium and
cells were incubated for two additional days before RNA extraction and
analysis.ata source
locationN/Aata accessibility Data is available within this article and available at the NCBI database via Gene
Expression Omnibus (GEO accession number GSE77345).Value of the data
 Provide information on genes regulated by 17β-HSD1 and its product estradiol, useful for further
studies on breast cancer cell mechanisms.
 Can contribute to elucidate hormone-independent cell growth pathways in hormone-dependent
breast cancer cells.
 May stimulate further research on understanding 17β-HSD1 roles in breast cancer development.1. Data
Table 1 showed data on gene expression proﬁle in T47D cells (genes regulated 1.5 time or higher)
transfected with 17β-HSD1 siRNAs (si17B1) or negative control siRNA (NC), and treated with 1 nM
Table 1
List of the 140 genes induced or repressed 1.5 time or higher (po0.05) in T47D cells after transfection with 17β-HSD1 siRNAs
(si17B1) or negative control siRNA (NC) for two days and cell treatment with 1 nM estradiol (E2). Data was obtained from
microarray analysis using contrast NCþE2 vs. si17B1þE2 (see Table 5).
Symbol Description Fold change
CDH10 Cadherin 10, type 2 (T2-cadherin) 5,2
IFI44 Interferon-induced protein 44 4,7
IFIT2 Interferon-induced protein with tetratricopeptide repeats 2 4,6
IFIT3 Interferon-induced protein with tetratricopeptide repeats 3 4,4
RSAD2 Radical S-adenosyl methionine domain containing 2 4,3
DDX60L DEAD (Asp-Glu-Ala-Asp) box polypeptide 60-like 4,0
CCL5 Chemokine (C-C motif) ligand 5 3,4
IFIT1 Interferon-induced protein with tetratricopeptide repeats 1 3,4
ARL4D ADP-ribosylation factor-like 4D 3,3
NAALADL2 N-acetylated alpha-linked acidic dipeptidase-like 2 3,2
BTN3A2 Butyrophilin, subfamily 3, member A2 3,1
LBA1 Lupus brain antigen 1 3,1
DDX60 DEAD (Asp-Glu-Ala-Asp) box polypeptide 60 3,0
XAF1 XIAP associated factor 1 2,9
MDGA2 MAM domain containing glycosylphosphatidylinositol anchor 2 2,9
OAS2 2'-5'-oligoadenylate synthetase 2, 69/71 kDa 2,9
RARRES3 Retinoic acid receptor responder (tazarotene induced) 2,9
HCP5 HLA complex P5 2,9
OASL 2'-5'-oligoadenylate synthetase-like 2,9
PARP14 Poly (ADP-ribose) polymerase family, member 14 2,8
IFITM3 Interferon induced transmembrane protein 3 (1-8U) 2,8
LAMP3 Lysosomal-associated membrane protein 3 2,7
AKAP6 A kinase (PRKA) anchor protein 6 2,7
PSMB9 Proteasome subunit beta type-9 2,7
BTN3A1 Butyrophilin, subfamily 3, member A1 2,7
RANBP3L RAN binding protein 3-like 2,6
HLA-F Major histocompatibility complex, class I, F 2,5
IFITM1 Interferon induced transmembrane protein 1 (9–27) 2,5
DDX58 DEAD (Asp–Glu–Ala–Asp) box polypeptide 58 2,5
BTN3A3 Butyrophilin, subfamily 3, member A3 2,5
ERBB4 V-erb-a erythroblastic leukemia viral oncogene homolog 4 (avian) 2,5
HLA-H Major histocompatibility complex, class I, H (pseudogene) 2,4
HLA-A Major histocompatibility complex, class I, A 2,4
PARP9 Poly (ADP-ribose) polymerase family, member 9 2,4
HLA-C Major histocompatibility complex, class I, C 2,3
CTSO Cathepsin O 2,3
L3MBTL3 L(3)mbt-like 3 (Drosophila) 2,3
HLA-E Major histocompatibility complex, class I, E 2,3
IFI35 Interferon-induced protein 35 2,3
HLA-B Major histocompatibility complex, class I, B 2,3
APOL1 Apolipoprotein L, 1 2,3
HLA-G Major histocompatibility complex, class I, G 2,3
HERC6 Hect domain and RLD 6 2,2
HERC5 Hect domain and RLD 5 2,2
IFIH1 Interferon induced with helicase C domain 1 2,2
SLC46A3 Solute carrier family 46, member 3 2,2
VGLL1 Vestigial like 1 (Drosophila) 2,2
TAP1 Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP) 2,2
FGF12 Fibroblast growth factor 12 2,2
PLSCR1 Phospholipid scramblase 1 2,2
HLA-A29,1 Major histocompatibility complex class I HLA-A29,1 2,2
LGALS3BP Lectin, galactoside-binding, soluble, 3 binding protein 2,2
SAMD9 Sterile alpha motif domain containing 9 2,2
ATP1B1 Atpase, Naþ/Kþ transporting, beta 1 polypeptide 2,1
OAS1 2',5'-oligoadenylate synthetase 1, 40/46kda 2,1
PSMB8 Proteasome subunit beta type-9 2,1
OAS3 2'-5'-oligoadenylate synthetase 3, 100kda 2,1
CENTD1 Centaurin, delta 1 2,1
J.A. Aka et al. / Data in Brief 9 (2016) 1000–10121002
Table 1 (continued )
Symbol Description Fold change
IFI27 Interferon, alpha-inducible protein 27 2,1
DHX58 DEXH (Asp–Glu–X-His) box polypeptide 58 2,1
STAT2 Signal transducer and activator of transcription 2, 113kda 2,0
LAMC1 Laminin, gamma 1 (formerly LAMB2) 2,0
THSD7A Thrombospondin, type I, domain containing 7A 2,0
TGFB2 Transforming growth factor, beta 2 2,0
USP18 Ubiquitin speciﬁc peptidase 18 2,0
MX1 Interferon-induced GTP-binding protein Mx1 2,0
B2M Beta-2-microglobulin 2,0
DTX3L Deltex 3-like (Drosophila) 2,0
ERAP1 Endoplasmic reticulum aminopeptidase 1 2,0
SLC15A3 Solute carrier family 15, member 3 1,9
CFB /// C2 Complement factor B /// complement component 2 1,9
TNFSF10 Tumor necrosis factor (ligand) superfamily, member 10 1,9
ROBO2 Roundabout homolog 2 1,9
IL1R1 Interleukin 1 receptor, type I 1,9
RAB27B RAB27B, member RAS oncogene family 1,9
RTP4 Receptor (chemosensory) transporter protein 4 1,9
STAT1 Signal transducer and activator of transcription 1, 91kda 1,9
CASP4 Caspase 4, apoptosis-related cysteine peptidase 1,9
INSIG2 Insulin induced gene 2 1,9
DKFZP434B2016 Similar to hypothetical protein LOC284701 1,9
SMARCA1 Nucleosome-remodeling factor subunit SNF2L 1,8
LIPH Lipase, member H 1,8
ZNFX1 Zinc ﬁnger, NFX1-type containing 1 1,8
UBP1 Upstream binding protein 1 (LBP-1a) 1,8
KLF8 Kruppel-like factor 8 1,8
LRRK2 Leucine-rich repeat kinase 2 1,8
LTBP1 Latent transforming growth factor beta binding protein 1 1,8
EVI1 Ecotropic viral integration site 1 1,8
FBXO32 F-box protein 32 1,7
BCAS1 Breast carcinoma ampliﬁed sequence 1 1,7
ALCAM Activated leukocyte cell adhesion molecule 1,7
MTERFD3 MTERF domain containing 3 1,6
MMP16 Matrix metallopeptidase 16 1,6
LOC390345 Similar to ribosomal protein L10 1,6
CITED2 Cbp/p300-interacting transactivator with Glu/Asp-rich carboxy-terminal domain 2 1,6
CYP4Z2P Cytochrome P450, family 4, subfamily Z, polypeptide 2 pseudogene 1,6
RNF43 Ring ﬁnger protein 43 1,6
ZNF175 Zinc ﬁnger protein 175 1,5
SEPP1 Selenoprotein P, plasma, 1 1,5
EPAS1 Endothelial PAS domain protein 1 1,5
FAM115A Family with sequence similarity 115, member A 1,5
SEMA6A Semaphorin 6A 1,5
NBEA Neurobeachin 1,5
CSAD Cysteine sulﬁnic acid decarboxylase 1,5
SNX24 Sorting nexin 24 1,5
RBBP8 Retinoblastoma binding protein 8 1,5
PTTG1 Pituitary tumor-transforming 1 1,5
ELOVL2 Elongation of very long chain fatty acids protein 2 1,5
KCTD6 Potassium channel tetramerisation domain containing 6 1,5
AURKA Aurora kinase A 1,5
KIF18A Kinesin family member 18A 1,5
ARHGAP11A Rho GTPase activating protein 11A 1,5
CDKN3 Cyclin-dependent kinase inhibitor 3 1,5
PRR11 Proline rich 11 1,5
C13orf3 Chromosome 13 open reading frame 3 1,5
SPAG5 Sperm associated antigen 5 1,6
CA8 Carbonic anhydrase VIII 1,6
PLK1 Polo-like kinase 1 (Drosophila) 1,6
SGOL1 Shugoshin-like 1 (S, pombe) 1,6
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Table 1 (continued )
Symbol Description Fold change
CCNA2 Cyclin A2 1,6
CDC20 Cell division cycle 20 1,6
NUF2 NUF2, NDC80 kinetochore complex component 1,6
KIF20A Kinesin family member 20A 1,6
ANP32E Acidic (leucine-rich) nuclear phosphoprotein 32 family, member E 1,7
RPL22 Ribosomal protein L22 1,7
PBK PDZ binding kinase 1,7
PTGES Prostaglandin E synthase 1,7
HEY2 Hairy/enhancer-of-split related with YRPW motif 2 1,8
SNORD27 Small nucleolar RNA, C/D box 27 1,8
SLC47A1 Solute carrier family 47, member 1 1,8
ESCO2 Establishment of sister chromatid cohesion N-acetyltransferase 2 1,9
C14orf129 Chromosome 14 open reading frame 129 1,9
FLNA Filamin A, alpha (actin binding protein 280) 1,9
CTSD Cathepsin D 2,0
RBM24 RNA binding motif protein 24 2,0
POLE3 Polymerase (DNA directed), epsilon 3 (p17 subunit) 2,1
LOC440093 Histone H3-like 2,2
AHNAK2 AHNAK nucleoprotein 2 2,2
AREG Amphiregulin 2,3
RCN2 Reticulocalbin 2, EF-hand calcium binding domain 2,3
Table 2
The 14 functional terms found in the cancer category of the IPA biological function analysis of
208 genes regulated by 17β-HSD1 and/or estradiol in T47D cells.
Number Functional term
1 Cancer
2 Breast cancer
3 Delay in tumorigenesis
4 Growth of tumor
5 Incidence of tumor
6 Mammary tumor
7 Neoplasia of tumor cell lines
8 Triple-negative breast cancer
9 Tumorigenesis of breast cancer cell lines
10 Tumorigenesis of cells
11 Tumorigenesis of mammary
adenocarcinoma
12 Tumorigenesis of mammary gland
13 Tumorigenesis of mammary tumor
14 Tumorigenesis of tumor cell lines
J.A. Aka et al. / Data in Brief 9 (2016) 1000–10121004estradiol (E2), revealed by microarray analysis with contrast NCþE2 vs. si17B1þE2 (see Table 5 for
additional information). Table 2 showed the 14 functional terms found in the cancer category of the
IPA biological function analysis of 208 genes from three fold change lists (genes which fold change
equal or higher than 1.5 in at least one contrast), generated by the three contrasts (NC vs. si17B1; NC
vs. NCþE2; and NCþE2 vs. si17B1þE2) of microarray analyses (see Table 5 for contrast description).
Table 3 showed the 14 functional terms found in the cell death and survival category of the IPA
biological function analysis of 208 genes generated by the three contrasts of microarray analyses.
Table 4 showed data on the IPA network analysis of 208 genes from the three contrasts (NC vs. si17B1;
Table 3
The 14 functional terms found in the cell death and survival category of the IPA Biological
function analysis of 208 genes regulated by 17β-HSD1 and/or estradiol in T47D cells.
Number Functional term
1 Apoptosis
2 Apoptosis of breast cancer cell lines
3 Apoptosis of breast cell lines
4 Apoptosis of mammary epithelial cells
5 Apoptosis of mammary tumor cells
6 Apoptosis of tumor cell lines
7 Cell death
8 Cell death of tumor cell lines
9 Cell survival
10 Cell viability
11 Cytotoxicity of cells
12 Cytotoxicity of cytotoxic T cells
13 Cytotoxicity of T lymphocytes
14 Necrosis
J.A. Aka et al. / Data in Brief 9 (2016) 1000–1012 1005NC vs. NCþE2; and NCþE2 vs. si17B1þE2) of the microarray analysis. Figs. 1–4 showed IPA Canonical
pathway analyses for interferon signaling pathway in the NC vs. NCþE2 contrast (Fig. 1), antigen
presentation pathway in the NC vs. si17B1 contrast (Fig. 2), antigen presentation pathway in the NC vs.
NCþE2 contrast (Fig. 3), and role of BRCA1 in DNA damage response in the NC vs. NCþE2 contrast
(Fig. 4).2. Experimental design, materials and methods
2.1. Cell culture, siRNA transfections, steroid treatment and RNA preparation
T47D cells were obtained from the American Type Culture Collection (ATCC) and were cultured as
described in ref [1]. The detailed procedure of siRNA transfections, steroid treatment and RNA pre-
paration have been described in ref [1]. Brieﬂy, two days before transfection, T47D cells were cultured
in dextran-coated charcoal-treated medium; on the transfection day, 3105 cells were reverse-
transfected in 6-well plates with 200 nM mixed 17β-HSD1 speciﬁc siRNAs [2,3] (si17B1) or with
Scramble siRNA used as negative control siRNA (NC) using Lipofectamine siRNAMax (Invitrogen), and
cells were incubated in steroid deprived medium. Two days after transfection, cell culture media were
replaced by fresh charcoal-treated medium containing either the steroid estradiol (1 nM) or ethanol
as a vehicle control (see Table 5), and cells were incubated for two more days before RNA extraction
using Trizol Reagent (Invitogen). The RNA samples included two independent biological replicates,
coming from two independent cell culture experiments, for a total of eight RNA samples.
2.2. Microarray processing
RNA samples were processed according to the manufacturer's recommended procedures on
GeneChip Whole Transcript (WT) Sense Target Labeling Assay from Affymetrix (http://www.affyme
trix.com/support/downloads/manuals/wt_sensetarget_label_manual.pdf). The assay was started with
0.2 mg of each T47D cells RNA samples and the protocol is based on the principle of performing one
cycle of cDNA synthesis and in vitro transcription (IVT) for target ampliﬁcation to generate cRNA
following by reverse transcription reactions to synthesis the WT cDNA. About 2.7 mg sample of
Table 4
IPA network analysis of 208 genes regulated by 17β-HSD1 and/or estradiol in T47D cells from the three contrasts listed in Table 5.
Molecules in Network: All of the molecules that compose each network are listed.
Score: The score is based on a p-value calculation, which calculates the likelihood that the Network Eligible Molecules that are part of a network are found therein by random chance
alone. Mathematically, the score is simply the negative exponent of the right-tailed Fisher's exact test result. For example, if the score is 3, then the there is a 1 in 1000 chance that the
Network Eligible Molecules found in that network appeared there just by chance. In other words, the score is simply a measure of the number of Network Eligible Molecules in a network,
and the greater the number of Network Eligible Molecules in a network, the higher the score (lower the p-value) will be.
Focus Molecules: This column simply indicates the number of Network Eligible Molecules per network. Since the maximum number of molecules per network is currently limited to 35,
the number of Network Eligible Molecules per network cannot exceed 35.
Top Functions: Only the three most signiﬁcant functions for each network are listed.
ID Molecules in network Score Focus molecules Top functions
1 2' 5' oas, Akt, DDX58, DDX60, DHX58, FBXO32, Fcer1, HERC5, IFIT1,
IFIT3, IFITM1, IFITM3, Ifn, IFN Beta, Interferon alpha, IRF, MX1, N-cor,
OAS1, OAS2, OAS3, Oas, PARP9, PBK, PI3K (family), RARRES3, RCN2,
RSAD2, SEMA6A, STAT2, STAT-1/2, Thioredoxin reductase, TXNRD1,
USP18, VTCN1
42 23 Antimicrobial response, inﬂammatory
response, inﬂammatory disease
2 Alpha catenin, Alpha tubulin, AREG/AREGB, Cadherin, CDH10, Cg,
CITED2, EPAS1, ERBB2, ERBB4, estrogen receptor, FKBP4, GNMT, GREB1,
Hdac, Histone h3, Hsp70, Hsp90, ID1, MCM10, PFKFB3, PGR, Pkc(s),
POLE3, PTGES, RBBP8, RNA polymerase II, RPL22, SMARCA1, SPINK4,
STC2, STEAP2, TCF, TM4SF1, Ubiquitin
38 22 Connective tissue development and function,
embryonic development, organ development
3 androstenediol, ARL4D, C5AR2, CD97, CSAD, CYP1A1, EID3, ESR1, FLRT3,
HLA-C, ICAM3, IL6, KCNF1, KCNH1, KCTD6, L3MBTL3, LRRK2, mir-19,
miR-149-3p (and other miRNAs w/seed GGGAGGG), miR-183-5p
(miRNAs w/seed AUGGCAC), miR-19b-3p (and other miRNAs w/seed
GUGCAAA), MTERFD3, NAALADL2, NMU, RAB27B, RAPGEFL1, RCN2,
RNF135, SLC46A3, SLC47A1, Slco1a1, SOX13, SPC25, THSD7A, TMEM116
38 21 Organismal injury and abnormalities, repro-
ductive system development and function,
reproductive system disease
4 ADRB, APC (complex), AURKA, BRCA2, BUB1, calpain, CASP4, caspase,
CCNA2, CCNB2, Cdc2, CDC20, Cdk, CKS2, Cyclin A, Cyclin B, Cyclin D,
Cyclin E, E2f, FLNA, Ifn gamma, MAP2K1/2, NDC80, NFkB (complex),
NFYB, NUF2, PLK1, PP2A, PTTG1, RAD51, Rb, RWDD2A, SGOL1, SPAG5,
XAF1
33 19 Cell cycle, cellular assembly and organization,
dna replication, recombination, and repair
5 AKAP8L, ANP32E, APEH, ARHGAP11A, BTN3A1, CEP152, DTX3L,
FAM115A, FBXO38, FDPS, FTSJ3, HMG CoA synthase, IFRD2, INSIG2,
KLF8, LGALS7/LGALS7B, LRRC41, MDGA2, NBEA, OAS3, PABPC4, PARP9,
PHF7, PPM1G, PRR11, PXMP4, RBM24, RHOBTB1, RNASEH2B, RNF43,
SKA3, SNRPA, SPC24, UBC, ZNF622
30 18 Hereditary disorder, neurological disease,
psychological disorders
6 20s proteasome, B2M, CD8, ERAP1, ERK1/2, H-2db, HLA Class I, HLA-A,
Hla-abc, HLA-B27, HLA-B, HLA-C, HLA-E, HLA-F, HLA-G, IFI27, IFI35,
IFI44, IFIH1, IFIT2, IFN alpha/beta, IFN type 1, Interferon-Î7 Induced,
ISGF3, KIR, LGALS3BP, MHC, MHC Class I (complex), MHC CLASS I
(family), MHC I-Î7 , PSMB8, PSMB9, Stat1-Stat2, TAP1, Tap
28 17 Endocrine system disorders, gastrointestinal
disease, immunological disease
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7 AHNAK2, ANKRD27, ARL8B, BRCA2, BTN3A3, CA8, CBX8, CEP170,
CKAP2L, CPAMD8, CTSL1, DDX6L, DLG5, DNPEP, ESCO2, EXOC1,
FAM72A, GOLGA4, HCST, HIC1, KIF18A, KIF20A, KIF4A, LIPH, LPXN,
MICB, PSMD14, RAB6A, RAB6B, SNX24, TAZ, TUBGCP2, UBC, ZNF175,
ZRANB2
28 17 Connective tissue disorders, dermatological
diseases and conditions, developmental
disorder
8 26s Proteasome, Actin, ARAP2, BTN3A2, C8orf44-SGK3/SGK3, FGF12,
GNB1, GNG11, GSK3B, GSKIP, HCP5, IFI35, IFNG, IFNL3, IL19, IRF, IRGM,
LAMP3, miR-21-5p (and other miRNAs w/seed AGCUUAU), MOV10,
MTORC2, Oas, PLA2, PSMB9, PSME2, RANBP3L, RSAD2, RTP4, SAMD9,
SLC15A3, SLC9A3, SOCS, STAT, uric acid, USP18
26 16 Dermatological diseases and conditions,
infectious disease, cell-to-cell signaling and
interaction
9 AKAP6, ALCAM, APOL1, CDKN3, CREBZF, CTSD, DDIT4, FBP1, FSH, Gsk3,
hemoglobin, HISTONE, Histone h4, IKK (complex), Insulin, KCNMA1, Lh,
Mapk, MYC, Notch, OASL, p85 (pik3r), Pka, PRKAC, Rac, Ras, Ras
homolog, ROBO2, SELENBP1, Shc, SOX2, TCR, TRIP13, Vegf, ZNFX1
25 16 Cellular growth and proliferation, tissue
development, cell morphology
10 Alp, Ap1, Cbp/p300, CCL5, CDCA5, Collagen type I, Collagen type IV,
Collagen(s), ELOVL2, ERK, Focal adhesion kinase, HEY2, IL1R1, Integrin,
JAK, KYNU, LAMC1, Laminin1, Laminin, LDL, LTBP1, Mek, MYB, p70 S6k,
Pdgf (complex), PDGF BB, Pias, PXK, Smad, Smad2/3, Sos, STAT5a/b, Tgf
beta, TGFB2, THBS1
18 12 Cardiovascular disease, embryonic develop-
ment, organ development
11 alpha-estradiol, androstenediol, ATP12A, ATP1B1, BCAS1, beta-estradiol,
CD40, Ck2, CTSO, EGFR, EGFR ligand, Egfr-Erbb2, ERBB, ganglioside
GD1a, GRM4, IER2, IFI30, IFNE, Igf, LTB, mir-146, miR-29b-3p (and other
miRNAs w/seed AGCACCA), Mmp, OLFM1, PTGDS, PVRL4, RAC1, RERG,
SEPP1, SERPINA6, TAP1, TP53INP1, UBP1, VGLL1, Wap
18 12 Cell morphology, cellular assembly and
organization, cellular development
12 AMPK, BCR (complex), CD3, cytochrome C, F Actin, HERC6, Hsp27, Ige,
IgG1, IgG, Igm, Ikk (family), IL1, IL12 (complex), IL12 (family), Immu-
noglobulin, Jnk, MECOM, MHC Class II (complex), MYBL1, P38 MAPK,
PARP14, PARP, PI3K (complex), PLC gamma, PLSCR1, Pro-inﬂammatory
Cytokine, Rsk, Rxr, S100A8, SRC (family), STAT1, Tlr, Tnf (family),
TNFSF10
10 8 Cellular development, hematological system
development and function, hematopoiesis
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Table 5
Summary of the cell experiments and microarray analyses.
T47D cell transfections and treatment
Time Experiments Well 1 Well 2 Well 3 Well 4
Day
1
Transfection with negative
control (NC) or 17β-HSD1
(si17B1) siRNAs
NC si17B1 NC si17B1
Day
3
Addition of estradiol
(þE2) or the vehicle
control ()
– – þE2 þE2
Day
5
Cell wash and total
RNA extraction
NC si17B1 NCþE2 si17B1þE2
Microarray analyses
Three contrasts Contrast 1: NC vs. si17B1 Contrast 2: NC vs. NCþE2 Contrast 3: NCþE2
vs. si17B1þE2
Aim List T47D genes impacted
by 17β-HSD1 knockdown in
steroid-deprived medium
List genes responsive to
estrogen in T47D
To detect if E2
impacts gene reg-
ulation by 17β-HSD1
knockdown
Fig. 1. IPA Canonical Pathway analysis showing the interferon signaling pathway across the NC vs. NCþE2 contrast data.
J.A. Aka et al. / Data in Brief 9 (2016) 1000–10121008fragmented cDNAs was used to hybridize human oligonucleotide array Gene 1.0 ST (Genechip;
Affymetrix). The array comprised more than 750,000 unique 25-mer oligonucleotides constituting
over 28,000 gene-level probe sets of the human genome. The cDNA probe corresponding to each
biological repetition for each condition was hybridized on separate arrays. After hybridization, chips
were processed using the Affymetrix GeneChip Fluidic Station 450 (protocol F450_0007). Chips were
scanned with a GeneChip scanner 3000 7G (Affymetrix) and images were extracted with the
Fig. 2. Canonical pathways by IPA: antigen presentation pathway in the NC vs. si17B1 contrast.
J.A. Aka et al. / Data in Brief 9 (2016) 1000–1012 1009GeneChip operating software (Affymetrix GCOS v1.4). The microarray processing was performed at
the DNA Biochip Platform service at CHU de Québec - CHUL Research Centre (Québec, Canada).
2.3. Microarray analysis
The microarray analysis has been described in the accompanying paper [1]. Quantiﬁed Affymetrix
image ﬁles (".CEL" ﬁles) for each of the treatment conditions (including two independent replicates
per treatment condition) were used to perform the microarray analyses using the Bioconductor
package OneChannelGUI [4,5] in the statistical software environment R. Three contrasts (see Table 5)
were using the RMA method [6]. Data ﬁltering was performed at signal feature level by interquantile
range (IQR) then by intensity. To identify differentially expressed genes, gene expression intensity was
compared using a moderated t-test and a Bayes smoothing approach developed for a low number
of replicates [7], and the false discovery rate was estimated from P-values derived from the moderated
t-test statistics for correction for the effect of multiple testing [8]. Genes were considered to be sig-
niﬁcantly differentially expressed if p-values were o0.05. The log2 transformed signal intensities
Fig. 3. Canonical pathways by IPA: antigen presentation pathway in the NC vs. NCþE2 contrast.
J.A. Aka et al. / Data in Brief 9 (2016) 1000–10121010were averaged, and the mean value was used to compute the fold changes. Genes that were differ-
entially expressed 1.5-fold or higher were considered for subsequent analyses. Our microarray data is
available in the Gene Expression Omnibus (GEO) repository, accession number GSE77345.2.4. Functional enrichment analysis
Ingenuity pathway analysis (IPA
s
, QIAGEN Redwood City, www.qiagen.com/ingenuity) was used to
assess the functional enrichment of the 208 modulated genes revealed by the three-contrast
microarray analysis (genes which fold change equal or higher than 1.5 in at least one contrast).
Three analyses made by IPAwere presented here: identiﬁcation of biological functions, gene networks
and canonical pathways (see ref for additional information). Criteria used for the IPA analyses have
been described in the accompanying research article [1].
Fig. 4. Canonical pathways by IPA: role of BRCA1 in DNA damage response in the NC vs. NCþE2 contrast.
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